FDA Approves Zimrixby (rituximab-cdxx), a Biosimilar to Rituxan

RegulatoryapprovedZimrixbyRituxanPositive

AI Analysis

Summary

The FDA approved Zimrixby (rituximab-cdxx), a biosimilar to Rituxan developed by Dr. Reddy's Laboratories and announced by Fresenius Kabi. This regulatory approval represents a significant milestone for the biosimilar market.

Outcome Details

FDA approved Zimrixby (rituximab-cdxx), a biosimilar to Rituxan

Importance:8/10

Sentiment:

0.75

FDA ApprovalBiosimilarRegulatoryDr. Reddy's Laboratories

Related Companies

$FMCQF $RDY $FMCQF

Read the original article

Published by Drugs.com New Drug Approvals on August 3, 2026 9:08 PM

Read Original